Stephen John Atkinson,Michael David Barker,Matthew Campbell,Hawa Diallo,Clement Douault,Neil Stuart Garton,John Liddle,Robert John Sheppard,Ann Louise Walker,Christopher Wellaway,David Matthew Wilson
申请号：
US15817562
公开号：
US20180161316A1
申请日:
2017.11.20
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Compounds of formula (I) wherein； R1 is hydrogen or C1-6alkyl； R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O—, or C1-6alkoxy； R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl； R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl； or unsubstituted C3-6cycloalkylC1-6alkyl； A is C—R5 or N； B is C—R6 or N； D is C—R7 or N； with the proviso that at least one of A, B, and D, is N； R5 is hydrogen or C1-6alkyl； R6 is hydrogen or C1-6alkyl； R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy； R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen； R9 is hydrogen or hydroxy； R1o is hydrogen or C1-6alkyl； and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
